Russian scientists have completed research on a drug against anxiety disorders and depression
Avineiro company, a participant of the NTI NeuroNet market, has completed clinical trials of the anti-anxiety drug AVIANDRⓇ. The medicine will help people with generalized anxiety disorder and complications of the central nervous system after suffering from COVID-19. The leader of the NeuroNet working group, Andrey Ivashchenko, spoke about this.
The drug AVIANDRⓇ, being developed within the Neuropharma segment, has successfully completed the necessary clinical trials and is now at the registration stage. The drug has shown effectiveness in treating anxiety disorders, including those associated with the consequences of COVID-19. In addition, the drug has an antidepressant and anti-asthenic effect, does not cause drowsiness, increases vitality and increases a person’s performance,” said Andrey Ivashchenko. The expert noted that obtaining a registration certificate for Aviander is expected in the summer of 2023.
Anxiety disorders and depression are among the most common consequences of coronavirus. According to a March 2022 World Health Organization (WHO) report, the global prevalence of anxiety disorders and depression increased by 25% at the start of the COVID-19 pandemic. Another current problem is post-traumatic stress disorder (PTSD). It occurs as a result of experiencing a severe traumatic event, when a person is tormented by recurring, intrusive disturbing memories, dreams (for example, nightmares), depression or attacks of aggression, panic attacks, and so on. Drug therapy with anti-anxiety drugs makes it faster and easier to cope with these conditions and survive a difficult period.
The Avineiro LLC has been developing the drug AVIANDRⓇ since 2011. One of the advantages of the new medicine is that, unlike drugs available on the market, it does not cause addiction or withdrawal symptoms after stopping treatment. Also, when taking AVIANDRⓇ, endocrine disorders are not observed: weight gain and sexual dysfunction.
“Usually, from the start of taking medications for anxiety and depression, it takes 3-4 weeks before relief occurs, so often patients do not wait for any effect and stop taking it within the first 1-2 weeks. The drug AVIANDRⓇ quickly relieves symptoms of anxiety and thereby increases satisfaction with therapy and adherence to treatment,” added Ivashchenko.
In the coming years, scientists also plan to create an application that will allow patients to maintain feedback with their doctor when taking AVIANDRⓇ.
Source: https://inscience.news/